Carlsmed Statistics
Total Valuation
Carlsmed has a market cap or net worth of $267.05 million. The enterprise value is $174.67 million.
Important Dates
The last earnings date was Wednesday, February 25, 2026, after market close.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Carlsmed has 26.73 million shares outstanding. The number of shares has increased by 249.74% in one year.
| Current Share Class | 26.73M |
| Shares Outstanding | 26.73M |
| Shares Change (YoY) | +249.74% |
| Shares Change (QoQ) | +26.16% |
| Owned by Insiders (%) | 12.39% |
| Owned by Institutions (%) | 17.51% |
| Float | 9.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.29 |
| Forward PS | 3.67 |
| PB Ratio | 2.69 |
| P/TBV Ratio | 2.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.87, with a Debt / Equity ratio of 0.18.
| Current Ratio | 8.87 |
| Quick Ratio | 8.48 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.38 |
Financial Efficiency
Return on equity (ROE) is -47.62% and return on invested capital (ROIC) is -24.03%.
| Return on Equity (ROE) | -47.62% |
| Return on Assets (ROA) | -21.01% |
| Return on Invested Capital (ROIC) | -24.03% |
| Return on Capital Employed (ROCE) | -26.39% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $397,724 |
| Profits Per Employee | -$237,937 |
| Employee Count | 127 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 8.78 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.39 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 30.62 |
| Average Volume (20 Days) | 191,277 |
Short Selling Information
The latest short interest is 684,173, so 2.56% of the outstanding shares have been sold short.
| Short Interest | 684,173 |
| Short Previous Month | 623,507 |
| Short % of Shares Out | 2.56% |
| Short % of Float | 7.24% |
| Short Ratio (days to cover) | 2.61 |
Income Statement
In the last 12 months, Carlsmed had revenue of $50.51 million and -$30.22 million in losses. Loss per share was -$2.12.
| Revenue | 50.51M |
| Gross Profit | 38.04M |
| Operating Income | -30.57M |
| Pretax Income | -29.63M |
| Net Income | -30.22M |
| EBITDA | -30.29M |
| EBIT | -30.57M |
| Loss Per Share | -$2.12 |
Full Income StatementBalance Sheet
The company has $109.79 million in cash and $17.41 million in debt, with a net cash position of $92.38 million or $3.46 per share.
| Cash & Cash Equivalents | 109.79M |
| Total Debt | 17.41M |
| Net Cash | 92.38M |
| Net Cash Per Share | $3.46 |
| Equity (Book Value) | 98.87M |
| Book Value Per Share | 3.72 |
| Working Capital | 112.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.98 million and capital expenditures -$642,000, giving a free cash flow of -$29.62 million.
| Operating Cash Flow | -28.98M |
| Capital Expenditures | -642,000 |
| Depreciation & Amortization | 281,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -29.62M |
| FCF Per Share | -$1.11 |
Full Cash Flow StatementMargins
Gross margin is 75.31%, with operating and profit margins of -60.53% and -58.67%.
| Gross Margin | 75.31% |
| Operating Margin | -60.53% |
| Pretax Margin | -58.67% |
| Profit Margin | -58.67% |
| EBITDA Margin | -59.97% |
| EBIT Margin | -60.53% |
| FCF Margin | n/a |
Dividends & Yields
Carlsmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -249.74% |
| Shareholder Yield | -249.74% |
| Earnings Yield | -11.32% |
| FCF Yield | -11.09% |
Analyst Forecast
The average price target for Carlsmed is $20.25, which is 102.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.25 |
| Price Target Difference | 102.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Carlsmed has an Altman Z-Score of 6.43 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.43 |
| Piotroski F-Score | 4 |
